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Abstract
Background—Multiple phase-2 trials in men with biochemically-recurrent prostate cancer 
(BRPC) have assessed the impact of non-hormonal agents on PSA kinetics. We have previously 
demonstrated that changes in PSA kinetics correlate with metastasis-free survival; however, it is 
unknown whether these changes also correlate with overall survival (OS).
Methods—We performed a combined retrospective analysis of 146 men with BRPC treated on 
phase-2 trials using one of four investigational drugs: lenalidomide (n=60), marimastat (n=39), 
ATN-224 (n=22), and imatinib (n=25). We examined factors influencing OS, including within-
subject changes in PSA kinetics (PSA slope, PSA doubling time, and PSA velocity) before and 6 
months after treatment initiation.
Results—After a median follow up of 83.1 months, 49 of 146 men had died. In univariate Cox 
regression analysis, two factors were associated with OS: baseline PSA velocity and change in 
PSA velocity on therapy. In a landmark multivariable model, stratified by study (which controlled 
for age, Gleason score, type of local therapy, and use of ADT prior to metastases), baseline PSA 
velocity and increase in PSA velocity on therapy remained independent predictors of OS. Median 
OS for men with an increase in PSA velocity on treatment was 115.4 months and was not reached 
for men with a decrease in PSA velocity (HR=0.47, 95% CI 0.25 to 0.88; P=0.02).
Conclusions—This hypothesis-generating study suggests that within-subject changes in PSA 
velocity after initiation of non-hormonal therapy may correlate with OS in men with BRPC. If 
validated in prospective trials, change in PSA velocity may represent a reasonable intermediate 
endpoint for screening new agents in these patients.
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Introduction
In men with biochemically-recurrent prostate cancer (BRPC) following definitive local 
therapy, there is currently no consensus on optimal management.(1,2) Although there are 
multiple potential treatment options, none has yet demonstrated an overall survival benefit, 
with a meta-analysis demonstrating decreased prostate cancer-specific survival but no 
increase in overall survival in men treated with early compared with deferred androgen-
deprivation therapy (ADT).(3) Nevertheless, given the large proportion of men in this 
clinical state, there remains great interest in developing therapeutic strategies for BRPC that 
may provide a survival benefit.
Hormone-sparing therapies have been developed for BCPC with the intention of avoiding 
the harms of prolonged ADT. To this end, a large number of biological and immunological 
agents have been evaluated in phase-2 clinical trials in these patients.(4-10) However, the 
lack of optimal study endpoints has hampered the development of such agents as the long 
interval between biochemical recurrence and death (or metastatic progression) leads to 
difficulty in demonstrating an overall survival benefit. In addition, even metastasis-free 
survival is not a validated endpoint in this setting.(11)
Because of the inability to follow radiographic or clinical parameters in this setting, the 
majority of such studies have utilized changes in PSA kinetics (PSA doubling time, PSA 
slope, and PSA velocity) as their primary endpoint. Change in PSA kinetics (specifically 
PSA decline ≥30%) has been demonstrated to meet Prentice surrogacy criteria for overall 
survival in the first-line chemotherapy setting in metastatic castration-resistant prostate 
cancer.(12,13) However, it is unclear whether changes in PSA kinetics may predict overall 
survival in the setting of BRPC following treatment with non-hormonal agents and whether 
these may serve as effective intermediate endpoints.
We have previously conducted four phase-2 trials investigating experimental non-hormonal 
agents in men with PSA-recurrent prostate cancer after local therapy.(5,6,8) All of these 
studies examined changes in PSA kinetics before and during study drug initiation as their 
primary endpoint. In an initial combined analysis of these 4 trials, we demonstrated that 
changes in PSA kinetics resulting after treatment initiation predicted metastasis-free survival 
(MFS) interval.(14) The present study is an update of the prior analysis of these four trials (n 
= 146), aiming to investigate the potential relationship between intra-subject changes in PSA 
kinetics and overall survival. We hypothesized that improvements in PSA kinetics after 
initiation of non-hormonal treatments would correlate with prolonged overall survival.
Methods
Study Design
The designs of the four phase-2 studies included in this combined analysis have been 
described previously.(5,6,8) The first study(5) was a randomized phase I/II trial evaluating 3 
doses of an oral matrix metalloproteinase inhibitor, marimastat (5 mg, 20 mg, or 40 mg 
daily). A total of 39 patients were enrolled, and the primary efficacy endpoint was change in 
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median PSA slope after 6 months of the study drug. The second trial(6) was a single-arm 
phase II study of the oral tyrosine kinase inhibitor, imatinib (800 mg daily). A total of 25 
men participated, and the primary endpoint was PSA response rate defined as a 50% 
decrease in PSA from baseline. The third study(8) was a randomized phase-2 trial of two 
doses of an oral copper/zinc-superoxide dismutase inhibitor, ATN-224 (30 mg or 300 mg 
daily). A total of 47 patients were accrued, and the primary endpoint was change in mean 
PSA slope and mean PSA doubling time on study. The fourth trial(15) was a randomized 
phase-1/2 study evaluating the oral immunomodulatory drug, lenalidomide (5 mg or 25 mg 
daily). A total of 60 men were enrolled, and the primary endpoint was change in median 
PSA slope after 6 months. None of these trials were designed a priori to capture data on 
overall survival.
All four studies were conducted at the Johns Hopkins Sidney Kimmel Comprehensive 
Cancer Center, Baltimore, MD. Three trials were single-center experiences while the 
ATN-224 study was also performed at 5 other centers. In all studies, eligible patients were 
required to have PSA-recurrent prostate cancer after local therapy, non-castrate levels of 
serum testosterone, non-metastatic disease as determined by CT and/or bone scan, and rising 
PSA levels. All trials used experimental agents that were not expected to mediate their 
effects through the endocrine axis. While on study, patients were required to have PSA 
assessments either every month (marimastat, ATN-224) or every 2 months (imatinib, 
lenalidomide). Patients were treated with study drug for either 6 months (marimastat, 
ATN-224, lenalidomide) or 12 months (imatinib). In all trials, patients came off study upon 
PSA progression, clinical/radiographic progression, unmanageable toxicity, or death 
(whichever occurred first).
The present study was a post hoc analysis of OS using combined data from these four 
phase-2 studies. We retrospectively examined patient records and/or death certificates for 
information on date and cause of death. OS was defined as the time interval from study entry 
until death from any cause. Patients were captured at the time of their death or censored at 
the time of the last known date on which they were alive. The data cut-off date was set as 
October 31st, 2013. This study was approved by the Johns Hopkins University IRB.
Statistical Analysis
The primary objective was to determine the independent contribution of changes in PSA 
kinetics on OS. PSADT was calculated as the slope of the simple linear regression of 
log(base 2) PSA vs time.(16) PSA velocity was calculated as the slope of the simple linear 
regression of PSA (natural scale) vs time.(17) PSA slope was calculated as the slope of the 
simple linear regression of the natural log of PSA vs time.(16) Event-time distributions for 
OS were estimated using the Kaplan-Meier method(18) and 95% confidence intervals (CIs) 
were calculated using the Brookmeyer-Crowley method.(19) Landmark stratified Cox 
proportional hazards regressions were used to assess the effects of PSA kinetics on OS. 
Models were stratified by study, and the landmark time was set at 6 months, because all 
PSA values during the first 6 months after study entry were used to calculate on-study PSA 
kinetics. Such a landmark analysis prevents death events that might occur during the first 6 
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months on-study to be included in the analysis. Our multivariable models were stratified by 
study to avoid assuming proportional hazards across the 4 different protocols.
In the univariate analysis, factors that entered the model included age (continuous variable), 
Gleason score (<7 vs. ≥7), tumor stage (T1/2 vs. T3/4), lymph node involvement (N0 vs. 
N1), modality of primary therapy (surgery ± radiotherapy vs. radiotherapy alone), ADT use 
prior to metastasis (yes vs. no), baseline PSA values, baseline PSADT (≥6 vs. <6 months), 
baseline PSA velocity (dichotomous [below vs. above median] and continuous), baseline 
PSA slope (dichotomous [below vs. above median] and continuous), change in PSADT 
before and after study initiation (dichotomous [decrease in PSADT vs. no decrease]), change 
in PSA velocity (dichotomous [increase in velocity vs. no increase] and continuous), and 
change in PSA slope (dichotomous [decrease in slope vs. no decrease] and continuous). 
Negative PSADT values were assigned an arbitrarily large constant value and thus PSADT 
could not be analyzed as a continuous variable. In multivariable analysis, covariates with P-
values from the univariate model of ≤0.10 as well as variables felt to be of potential clinical 
importance (including age, Gleason score, and pre-metastatic use of ADT) were included. 
Notably, because all three PSA kinetic measures are a function of changes in PSA against 
time and are all strongly interrelated, three separate multivariable models (each evaluating 
one kinetic measure at a time) were created.
All P-values are two-sided, and the significance level was set at ≤0.05. Statistical analyses 
were performed using SAS version 9.2 (SAS Institute Inc, Cary, NC) and R version 3.1.0 
(National Cancer Institute, Bethesda, MD).
Results
Patient Characteristics
Table 1 describes the clinical characteristics of men in each of the four trials. Twenty-five of 
47 patients in the ATN-224 study (those enrolled at the other sites), did not have available 
data on survival status and were thus excluded from the analysis. All 39 patients in the 
marimastat study, all 25 patients in the imatinib study, and all 60 patients in the 
lenalidomide study had full information available to determine OS. With a median follow-up 
in the combined evaluable cohort of 83.1 months (95% CI, 78.8 to 114.3), 49 of 146 
(33.6%) men had died.
Overall (n=146), median age at study entry was 63 years; 58 men (40%) had primary 
prostatectomy, 27 (18%) had primary radiotherapy, and 61 (42%) had prostatectomy and 
salvage radiotherapy; 26 men (18%) had Gleason score ≤6, 74 (51%) had Gleason score 7, 
and 46 (31%) had Gleason score ≥8; 12 men (8%) had T1 disease, 47 (32%) had T2 disease, 
and 87 (60%) had T3 disease; 16 men (11%) had node-positive disease at diagnosis; and 36 
men (25%) received ADT prior to metastatic progression. Median PSA at baseline was 7.7 
ng/mL; median PSA doubling time at baseline was 5.0 months; median PSA slope at 
baseline was 0.14; and median PSA velocity at baseline was 0.59 ng/mL/month.
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Correlation of Changes in PSA Kinetics with OS
In univariate proportional hazards regression analyses (stratified by study), significant 
associations with OS were observed for: baseline PSA velocity (dichotomized) and change 
in PSA velocity (dichotomized and continuous). (Table 2).
Figure 1 demonstrates the effect of changes in PSADT (increase in PSADT after study entry 
vs. no increase), changes in (log) PSA slope (decrease in PSA slope vs. no decrease), and 
changes in PSA velocity (decrease in PSA velocity vs. no decrease) on OS using Kaplan-
Meier analysis, when these factors were considered as dichotomous variables. While there 
were trends between slowing of PSA kinetics and improved OS, only the change in PSA 
velocity was significantly prognostic for OS.
In landmark multivariable analyses when these factors were considered as dichotomous 
variables (Table 3), change in PSA velocity emerged as a significant independent predictor 
of OS. The HR was 0.52 (95% CI 0.27 to 1.00; P = 0.05), indicating a 48% decrease in risk 
of death if PSA velocity decreased following treatment. Sensitivity analyses for the chosen 
cut points are reported in the supplemental appendix (supplemental Tables 1-6). However, 
baseline PSADT, baseline (log) PSA slope, change in PSADT, and change in (log) PSA 
slope, which were independent predictors of metastasis-free survival (MFS) in the prior 
analysis, did not retain statistical significance as predictors of OS, either in the univariate or 
multivariate analyses (Table 3).
In landmark multivariable analyses when these factors were considered as continuous 
variables (Table 4), both change in PSA velocity (HR = 1.07; 95% CI 1.03 to 1.11; P < 0.01) 
and change in (log) PSA slope (HR 9.91, 95% CI 1.54 to 63.93; P = 0.02) were independent 
predictors of OS.
Discussion
In men with hormone-naïve biochemically-recurrent prostate cancer after local therapy, 
there is a need for surrogate endpoints of clinical benefit given the long natural history of 
this disease state.(20,21) Changes in PSA kinetics offer an attractive intermediate endpoint 
given evidence that changes in kinetics following non-hormonal therapy may predict MFS 
based on our prior analysis of this dataset.(20,21)
This study represents an update to the prior analysis based on extended follow-up for OS. 
Here, we demonstrate that men whose PSA velocity decreased after study entry had 
improved OS, a correlation which remained significant after accounting for relevant clinical 
factors and pre-treatment PSA velocity. In other settings, PSA velocity >2.0 ng/mL prior to 
either radical prostatectomy or radiation therapy has been demonstrated to predict inferior 
overall survival(17,22), while high PSA velocity post-relapse predicts failure of salvage 
radiotherapy.(23) However, to our knowledge, this study is the first to document a correlation 
between on-study changes in PSA velocity and overall survival in men with BRPC receiving 
non-hormonal therapies.
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Interestingly, although dichotomized changes in PSA slope and PSADT were significant 
independent predictors of MFS in our prior analysis, these only demonstrated a non-
significant trend towards predicting OS in the current analysis. Due to the relatively small 
number of death events observed to date, minor changes in patient classification between the 
different PSA kinetic schemes may have resulted in significant effects on the statistical 
analysis. However, continuous change in PSA slope was significantly associated with OS, 
suggesting that an optimal cut point may be able to be identified in a larger cohort.
These results corroborate data from prior studies that demonstrated associations between 
changes in PSA in response to hormonal therapy. In one study, a PSA of ≤4 ng/mL after 7 
months of ADT in men with metastatic hormone-sensitive prostate cancer predicted OS, as 
did PSA progression within that timeframe.(13) In a second study, PSA changes in men 
undergoing either mitoxantrone or docetaxel chemotherapy met Prentice surrogacy criteria 
for prediction of OS.(12) Specifically, PSA declines of ≥30% in response to chemotherapy 
predicted OS, although interestingly a decline of ≥50% failed the ‘proportion-of-treatment-
effect-explained’ (PTE) test. Of note, PSA velocity at either 2 or 3 months post-therapy also 
satisfied Prentice criteria. Surrogacy of changes in PSA kinetics was subsequently 
demonstrated in the TAX327 study evaluating first-line docetaxel chemotherapy(24), 
although a recent analysis of the TROPIC trial of cabazitaxel failed to demonstrate that early 
changes in PSA fully captured changes in survival, suggesting that PSA is not an appropriate 
surrogate endpoint in the second-line chemotherapy setting(25). The present study adds to 
this body of evidence, and suggests that changes in PSA velocity in men with BRPC 
receiving non-hormonal therapies may correlate with OS.
This study has several limitations. First, this was a retrospective study and none of the four 
trials included in the combined analysis were designed to capture data on survival. In 
addition, because the majority of death events occurred after patients had been taken off-
study, a significant proportion of patients were lost to follow-up. Further, as a consequence 
of a retrospective analysis, it is generally difficult to determine whether the variable of 
interest (i.e. change in PSA kinetics, in this case) actually influences survival or if it simply 
acts as a marker of a more favorable prognosis. This is also true of the other baseline factors 
in the multivariable analysis including baseline velocity. Second, we had no control over 
additional therapies (including hormonal therapy, chemotherapy, or other novel therapies) 
administered to patients after they came off-study in each of the four trials; such subsequent 
therapies may have influenced OS.
Finally, the causal relationship between the study drugs and PSA kinetics changes cannot be 
proven in the absence of placebo-control trials. Changes in PSA kinetics after study entry, 
for example, may have been caused by more frequent PSA assessments on-study compared 
to pre-study PSA evaluations (which would not have been regulated). To this end, in a 
placebo-controlled trial evaluating the effect of celecoxib on PSADT in a similar patient 
population, 20% of 40 men in the placebo group had a post-treatment PSADT that was 
≥200% of baseline.(7) A recent analysis confirms the natural variability of PSA kinetic 
parameters even in the absence of therapy.(26) Phrased alternatively, there is no direct 
evidence that on-study PSA kinetics were induced by the study drugs tested. Furthermore, 
these agents have not individually demonstrated improvements in survival, neither as a 
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primary endpoint nor in pre-defined subset analyses. Ultimately, the findings of this study 
will require confirmation in prospective trials using more effective agents as well as longer 
and more regimented follow-up.
In conclusion, this hypothesis-generating analysis suggests that within-subject changes in 
PSA velocity and PSA slope (but not PSADT) after initiation of non-hormonal experimental 
therapies may correlate with survival in men with PSA-recurrent prostate cancer. 
Additionally, an intuitive cutpoint of increase vs decrease in PSA velocity after therapy was 
found to correlate with OS. If these findings are validated in prospective trials using survival 
as the primary endpoint, changes in PSA velocity may represent a reasonable intermediate 
endpoint for screening new non-hormonal agents in this patient population moving forward. 
This may facilitate more rapid advancement of promising non-hormonal agents into larger 
randomized trials with a primary survival endpoint. Given the long natural history of PSA-
recurrent prostate cancer, a robust intermediate endpoint is critical. Ultimately, 
corroboration of these findings will require satisfaction of the Prentice criteria in the setting 
of randomized, placebo-controlled trials demonstrating a survival benefit in men with 
biochemically-recurrent prostate cancer.
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Figure 1. 
Overall survival stratified by (A) dichotomous change in PSA doubling time (stratified log-
rank test p=0.41), (B) change in (log) PSA slope (stratified log-rank test p=0.41), and (C) 
change in PSA velocity (stratified log-rank test p=0.02).
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Table 1
Patient Baseline Characteristics
Characteristic Trial
Marimastat (n = 39) Imatinib (n = 25) ATN-224 (n = 22) Lenalidomide (n = 60)
Minimum PSA requirement for trial 
entry
 PSA PSA ≥1.0 ng/mL PSA ≥1.0 ng/mL PSA ≥2.0 ng/mL PSA ≥1.0 ng/mL
PSADT requirement for trial entry
 PSADT Any PSADT Any PSADT PSADT ≤12 months Any PSADT
Age, y
 Mean (range) 61 (48 to 77) 65 (50 to 77) 62 (53 to 75) 63 (50 to 81)
 Median 58 67 63 64
Local therapy
 Prostatectomy only 19 (49%) 5 (20%) 10 (45%) 24 (40%)
 Radiotherapy only 4 (10%) 9 (36%) 3 (14%) 11 (18%)
 Both 16 (41%) 11 (44%) 9 (41%) 25 (42%)
Gleason score
 ≤6 0 (0%) 8 (32%) 5 (23%) 13 (22%)
 7 24 (62%) 12 (48%) 7 (32%) 31 (51%)
 ≥8 15 (38%) 5 (20%) 10 (45%) 16 (27%)
T stage
 T1 0 (0%) 5 (20%) 0 (0%) 7 (12%)
 T2 7 (18%) 10 (40%) 12 (55%) 18 (30%)
 T3 32 (82%) 10 (40%) 10 (45%) 35 (58%)
N stage
 N0 34 (87%) 25 (100%) 18 (82%) 53 (88%)
 N1 5 (13%) 0 (0%) 4 (18%) 7 (12%)
Use of ADT before metastases
 No 27 (69%) 13 (52%) 17 (77%) 53 (88%)
 Yes 12 (31%) 12 (48%) 5 (23%) 7 (12%)
Baseline PSA, ng/mL
 Median (Range) 9.6 (1.2 to 59.7) 8 (2.1 to 221) 4.4 (0.7 to 33.5) 7.5 (0.9 to 77.4)
Baseline PSA doubling time, mo
 Median (Range) 4.7 (1.4 to 12.8) 9.2 (1.1 to 30.4) 3.9 (1.2 to 12.2) 4.6 (1 to 58.9)
Baseline PSA slope
 Median (Range) 0.15 (0.05 to 0.49) 0.08 (0.02 to 0.62) 0.18 (0.06 to 0.56) 0.15 (0.01 to 0.71)
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Characteristic Trial
Marimastat (n = 39) Imatinib (n = 25) ATN-224 (n = 22) Lenalidomide (n = 60)
Baseline PSA velocity, ng/mL/mo
 Median (Range) 0.4 (0 to 3.9) 0.6 (0.1 to 2.7) 0.7 (0.1 to 16.3) 0.6 (0 to 9.4)
Follow-up Duration, mo
 Median (range) 157.0 (154.2 to 164.4) 126.7 (118.7 to NA) 73.7 (68.9 to 78.8) 83.1 (78.8 to 114.3)
Deaths 18 (46%) 11 (44%) 5 (23%) 15 (25%)
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Table 2
Stratified Univariate Cox Regression Analyses for Predicting Overall Srvival in Men with 
PSA-Recurrent Prostate Cancer Enrolled in All 4 Trials
Variable Univariate analysis
HR (95% CI) p-value
Age, y (continuous) 0.98 (0.94 to 1.02) 0.36
Local therapy
 Surgery (±radiotherapy) 0.65 (0.33, 1.3) 0.23
 Radiotherapy only 1 [reference]
Gleason score
 >7 0.97 (0.41 to 2.27) 0.94
 ≤7 1 [reference]
T stage
 T1-2 0.75 (0.4 to 1.4) 0.37
 T3 1 [reference]
N stage
 N0 0.94 (0.36 to 2.42) 0.90
 N1 1 [reference]
Use of ADT prior to metastases
 Yes 0.55 (0.27 to 1.12) 0.10
 No 1 [reference]
Baseline PSA (continuous) 1.00 (0.98 to 1.01) 0.57
Baseline PSA Velocity
 Below median (=0.59 ng/mL/mo) 0.47 (0.26 to 0.84) 0.01
 Above median 1 [reference]
 Continuous 0.99 (0.81 to 1.2) 0.90
Δ in PSA velocity
 Decrease 0.47 (0.25 to 0.88) 0.02
 No decrease 1 [reference]
 Continuous 1.06 (1.02 to 1.1) <0.01
Baseline PSADT (mo)
 ≥6 0.63 (0.33 to 1.18) 0.147
 <6 1 [reference]
Δ in PSADT
 Increase 0.75 (0.39 to 1.44) 0.39
 No increase 1 [reference]
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Variable Univariate analysis
HR (95% CI) p-value
Baseline (log) PSA slope
 Below median (=0.14 log[ng/mL]/mo) 0.67 (0.37 to 1.23) 0.20
 Above median 1 [reference]
 Continuous 1.54 (0.18 to 12.91) 0.69
Δ in (log) PSA slope
 Decrease 0.75 (0.39 to 1.44) 0.39
 No decrease 1 [reference]
 Continuous 5.33 (0.94 to 30.09) 0.06
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Table 4
Stratified Landmark Multivariable Cox Regression Analyses for Predicting Overall 
Survival Considering the Effect of Continuous Changes in (A) (log) PSA slope, and (B) 
PSA velocity
(A) (log) PSA Slope (B) PSA Velocity
HR (95% CI) p-value HR (95% CI) p-value
Age, y (continuous) 0.97 (0.93 to 1.02) 0.23 0.97 (0.93 to 1.01) 0.17
Gleason score
 <7 0.98 (0.4 to 2.44) 0.97 0.96 (0.39 to 2.36) 0.93
 ≥7 1 [reference] 1 [reference]
Local therapy
 Surgery (±radiotherapy) 0.50 (0.23 to 1.42) 0.08 0.51 (0.24, 1.08) 0.08
 Local therapy 1 [reference] 1 [reference]
Use of ADT prior to metastases
 Yes 0.68 (0.32 to 1.42) 0.30 0.73 (0.35 to 1.52) 0.40
 No 1 [reference] 1 [reference]
Baseline PSADT (mo)
Δ in PSADT
Baseline (log) PSA slope 6.77 (0.52 to 88.17) 0.14
Δ in (log) PSA slope 9.91 (1.54 to 63.93) 0.02
Baseline PSA Velocity 0.96 (0.76 to 1.22) 0.76
Δ in PSA velocity 1.07 (1.03 to 1.11) <0.01
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